STEMI Trial Fails to Support Post-PCI Anticoagulation
The randomized RIGHT trial, testing 48 hours of post-PCI anticoagulation in STEMI patients, failed to document either benefit or increased risk.
Source: medscape.com
Pascal Vranckx News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Pascal Vranckx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Pascal Vranckx Today - Breaking & Trending Today
Many ACS Patients With Occlusions Are Falling Through the Cracks
NSTEMI patients with blockages are delayed getting to the cath lab and fare worse than their counterparts with STEMI.
Source: tctmd.com
One-Month DAPT Enough for Complex PCI if Bleeding Risk High
Latest data from the MASTER DAPT trial show similar results in the subgroup of patients who underwent complex PCI as in the main trial.
Source: medscape.com
Shorter DAPT Sufficient Even in Complex HBR Patients: MASTER DAPT
Complex HBR patients had the most to gain from longer DAPT, but even here, the shorter regimen seemed to hold up.
Source: tctmd.com
Subcutaneous GP IIb/IIIa Inhibitor in STEMI Is Fast, Potent in Early Study
May 18, 2021 RUC-4 (CeleCor Therapeutics), an investigational glycoprotein IIb/IIIa inhibitor (GPI) administered by subcutaneous injection, provides rapid and powerful platelet inhibition in patients with STEMI, according to findings from Cel-02, a phase IIa study. Average platelet inhibition 15 minutes after the injection increased across three doses, from 77.5% with the lowest dose to 87.5% with the middle dose and 91.7% with the highest dose ( P = 0.002 for trend), Jurriën ten Berg, MD, PhD (St. Antonius Hospital, Nieuwegein, the Netherlands), reported during the virtual EuroPCR 2021. RUC...
Source: tctmd.com